What we do

For more than 45 years we’ve been creating high-quality medicines and making them accessible to the people who need them.

Learn more about how we do this across North America, MENA and Europe.

Investors

Together we are building a leading generics and specialty pharmaceutical company where everyone can thrive.

Learn more about our strategy, investment case and track record of success.

Responsibility

Learn more about how we put better health within reach, every day and make a difference to people’s lives.

Careers

We're looking for people who share our passion and want to help us make a real difference in the world.

Newsroom

Press Release, Product 20 Dezember 2024

Hikma expands its agreement with AFT Pharmaceuticals for the commercialisation of injectable pain medication Combogesic® into the Saudi, Jordanian and Iraqi Markets Press Release, Business Development 12 Februar 2024 Hikma expands its agreement with AFT Pharmaceuticals for the commercialisation of injectable pain medication Combogesic® into the Saudi, Jordanian and Iraqi Markets
Hikma and Guardant Health sign exclusive partnership agreement to bring transformative cancer diagnostic technology to the Middle East and North Africa Press Release, Business Development 08 Januar 2024 Hikma and Guardant Health sign exclusive partnership agreement to bring transformative cancer diagnostic technology to the Middle East and North Africa
Hikma launches authorized generic of Xyrem® (sodium oxybate) in the US Press Release, Product 03 Januar 2023 Hikma launches authorized generic of Xyrem® (sodium oxybate) in the US
Hikma and Celltrion Healthcare sign new exclusive licensing agreement for Vegzelma® for the Middle East and North Africa region Press Release, Corporate 03 Januar 2023 Hikma and Celltrion Healthcare sign new exclusive licensing agreement for Vegzelma® for the Middle East and North Africa region